Related Experiment Videos
Thromboembolic complications associated with reproductive endocrinologic procedures
1Department of Obstetrics and Gynecology, Hutzel Hospital-Detroit Medical Center, Wayne State University, Michigan, USA. pbaumann@med.wayne.edu
Hematology/Oncology Clinics of North America
|May 12, 2000
Summary
Hormonal ovarian stimulation (OHS) for fertility treatments can rarely cause thromboembolism. Human chorionic gonadotropin (hCG), not just high estrogen, appears crucial in OHS development, even with low estrogen levels.
Area of Science:
- Reproductive endocrinology
- Thrombosis research
- In vitro fertilization
Background:
- Thromboembolism is a rare complication of hormonal ovarian stimulation (OHS) during assisted reproductive techniques.
- OHS is often associated with high serum estrogen concentrations, but the exact causative factors remain unclear.
Purpose of the Study:
- To investigate the role of human chorionic gonadotropin (hCG) and estrogen in the development of OHS.
- To elucidate the mechanisms underlying OHS, including fluid shifts and hypercoagulability.
Main Methods:
- Review of cases of OHS in women undergoing fertility treatments.
- Analysis of serum estrogen and hCG levels in affected individuals.
- Examination of evidence linking hormonal ovarian stimulation (HMG) and hCG ovulation induction to hypercoagulability.
Main Results:
- hCG appears to play a central role in OHS development, independent of high estrogen levels.
- OHS has been observed in conditions with low estrogen (17,18-desmolase deficiency) following hCG induction.
- Evidence suggests hormonal ovarian stimulation and hCG induction contribute to hypercoagulability.
Conclusions:
- hCG is implicated as a key factor in OHS, potentially more so than elevated estrogen.
- Further research is needed to fully understand the roles of estrogens, hCG, and fluid shifts in OHS pathophysiology.